Nucleic Acid Testing: A Vehicle for Advancing Personalized Medicine
Published By: Decision Resources
April 2009
R55-638
PDF E-mail From Publisher $2,250.00
Global Site License Fulfilled by Publisher $4,500.00
Description
Introduction
One of the fastest-growing segments of molecular diagnostics is nucleic acid testing (NAT). NAT is central to
the life sciences industry, to improved healthcare, and to personalized medicine. Tools based on NAT are used to
discover new biomarkers and develop in vitro diagnostics. Companies large and small are recognizing the value
of NAT, and both R&D and dealmaking activity is robust. Find out who the players are and how they are vying
for commercial success.
Get the Answers You Need to Shape Your Strategy
- NAT is a leading molecular diagnostics technology. What are the advantages of NAT over other molecular
diagnostics technologies? Which elements of NAT will drive personalized medicine forward?
- Polymerase chain reaction (PCR) is one of the most common methods in the NAT toolbox used to discover
new biomarkers and develop diagnostics tests. What other methods are commonly used for NAT? Which
of these methods have the most product development activity?
- Roche Diagnostics is the clear leader in molecular diagnostics. How do Roche’s sales fi gures compare with
those of smaller diagnostics players? What does the competition look like within the smaller segments?
How are companies using dealmaking to advance their positions?
- Infectious disease and oncology are the two main therapy areas for use of NAT technologies. What are the
growth trends and growth drivers within these therapy areas? What companies are positioned to tap
the opportunities?
Scope
- Importance of NAT for advancing personalized medicine: Use of and rationale for NAT techniques and
products to support the push for personalized medicine.
- Key mergers and acquisitions (M&As), collaboration, and licensing activities in NAT: Two tables featuring
92 alliances that occurred from November 2007 through December 2008.
- Leading NAT markets: Types of assays and tests within infectious disease and oncology that will
continue to have a strong presence in the NAT market.
- Future trends: Insight into strategic considerations required to drive the NAT market and NAT
companies forward.
|
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction to NAT—A Central Technology
- Driving the Evolution to Personalized Medicine
- Affecting Drug Discovery and Approval
- Leading the Molecular Diagnostic Assay Technologies
- Scope of the Report
- The NAT Toolbox: Technologies for Now and the Future
- Therapeutic Focus of the NAT Market
- Blood Screening and Infectious Diseases
- Testing for Sexually Transmitted Infections
- Hospital-Acquired Infections Testing
- HIV Drug Resistance Testing
- Infectious Respiratory Diseases
- Oncology
- Hereditary Risk Assays
- Early Detection Assays
- Targeted Therapy Assays
- Assays for Cancer Prognosis
- Assays Guiding Treatment Options
- Company Leaders in NAT
- Future Trends
- Applications That Will Drive the NAT Market for the Foreseeable Future
- Leading Companies in NAT Will Drive Growth Through Acquisitions and Licensing
- NAT Assays Are High Value, but Tests Need to Demonstrate Cost-Effectiveness
- Sidebar
- Using Discovery Tools to Shape Future NAT Oncology Assays
- Tables
- 1. The Nucleic Acid Testing Toolbox
- 2. Validated Genomic Biomarkers for Select Approved Agents
- 3. Select Nucleic Acid Testing Leaders, by Market Segment
- 4. Select Acquisitions in NAT, November 2007-December 2008
- Appendix A. Select Licensing and Collaboration Activities in NAT, November 2007-December 2008
- Figures
- 1. NAT Alliances in 2008, by Therapeutic Area
- 2. Algorithm for the Diagnosis of Chronic Hepatitis C
- 3. Cancer Molecular Targets
|
Order Form * Please reference product number R55-638 when ordering or inquiring.
MindBranch, Inc.,
131 Ashland St., Suite 200 North Adams, MA 01247
tel: 800-774-4410
fax: +1-413-664-9791
www.mindbranch.com
|
